Loss of function of ENT3 drives histiocytosis and inflammation through TLR-MAPK signaling

2.

Guilliams

M

,

Ginhoux

F

,

Jakubzick

C

, et al.

Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny

.

Nat Rev Immunol

.

2014

;

14

(

8

):

571

-

578

.

3.

Badalian-Very

G

,

Vergilio

JA

,

Degar

BA

, et al.

Recurrent BRAF mutations in Langerhans cell histiocytosis

.

Blood

.

2010

;

116

(

11

):

1919

-

1923

.

4.

Chakraborty

R

,

Hampton

OA

,

Shen

X

, et al.

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

.

Blood

.

2014

;

124

(

19

):

3007

-

3015

.

5.

Chakraborty

R

,

Burke

TM

,

Hampton

OA

, et al.

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis

.

Blood

.

2016

;

128

(

21

):

2533

-

2537

.

6.

Diamond

EL

,

Durham

BH

,

Haroche

J

, et al.

Diverse and targetable kinase alterations drive histiocytic neoplasms

.

Cancer Discov

.

2016

;

6

(

2

):

154

-

165

.

7.

Durham

BH

,

Lopez Rodrigo

E

,

Picarsic

J

, et al.

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

.

Nat Med

.

2019

;

25

(

12

):

1839

-

1842

.

8.

Donadieu

J

,

Larabi

IA

,

Tardieu

M

, et al.

Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study

.

J Clin Oncol

.

2019

;

37

(

31

):

2857

-

2865

.

9.

Durham

BH

.

Molecular characterization of the histiocytoses: neoplasia of dendritic cells and macrophages

.

Semin Cell Dev Biol

.

2019

;

86

:

62

-

76

.

10.

Molho-Pessach

V

,

Lerer

I

,

Abeliovich

D

, et al.

The H syndrome is caused by mutations in the nucleoside transporter hENT3

.

Am J Hum Genet

.

2008

;

83

(

4

):

529

-

534

.

11.

Molho-Pessach

V

,

Ramot

Y

,

Camille

F

, et al.

H syndrome: the first 79 patients

.

J Am Acad Dermatol

.

2014

;

70

(

1

):

80

-

88

.

12.

Avitan-Hersh

E

,

Mandel

H

,

Indelman

M

,

Bar-Joseph

G

,

Zlotogorski

A

,

Bergman

R

.

A case of H syndrome showing immunophenotye similarities to Rosai-Dorfman disease

.

Am J Dermatopathol

.

2011

;

33

(

1

):

47

-

51

.

13.

Colmenero

I

,

Molho-Pessach

V

,

Torrelo

A

,

Zlotogorski

A

,

Requena

L

.

Emperipolesis: an additional common histopathologic finding in H syndrome and Rosai-Dorfman disease

.

Am J Dermatopathol

.

2012

;

34

(

3

):

315

-

320

.

14.

Melki

I

,

Lambot

K

,

Jonard

L

, et al.

Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition

.

Pediatrics

.

2013

;

131

(

4

):

e1308

-

1313

.

15.

Kismet

E

,

Koseoglu

V

,

Atay

AA

,

Deveci

S

,

Demirkaya

E

,

Tuncer

K

.

Sinus histiocytosis with massive lymphadenopathy in three brothers

.

Pediatr Int

.

2005

;

47

(

4

):

473

-

476

.

16.

Bolze

A

,

Abhyankar

A

,

Grant

AV

, et al.

A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant

.

PLoS One

.

2012

;

7

(

1

):

e29708

.

17.

Baldwin

SA

,

Yao

SY

,

Hyde

RJ

, et al.

Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes

.

J Biol Chem

.

2005

;

280

(

16

):

15880

-

15887

.

18.

Hsu

CL

,

Lin

W

,

Seshasayee

D

, et al.

Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis

.

Science

.

2012

;

335

(

6064

):

89

-

92

.

19.

Abla

O

,

Jacobsen

E

,

Picarsic

J

, et al.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

.

Blood

.

2018

;

131

(

26

):

2877

-

2890

.

20.

Diamond

EL

,

Durham

BH

,

Ulaner

GA

, et al.

Efficacy of MEK inhibition in patients with histiocytic neoplasms

.

Nature

.

2019

;

567

(

7749

):

521

-

524

.

21.

Xiao

Y

,

van Halteren

AGS

,

Lei

X

, et al.

Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis

.

Blood

.

2020

;

136

(

19

):

2188

-

2199

.

22.

Berres

ML

,

Lim

KP

,

Peters

T

, et al.

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

.

J Exp Med

.

2014

;

211

(

4

):

669

-

683

.

23.

Milne

P

,

Bigley

V

,

Bacon

CM

, et al.

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

.

Blood

.

2017

;

130

(

2

):

167

-

175

.

24.

Eder

SK

,

Schwentner

R

,

Ben Soussia

P

, et al.

Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis

.

Blood Adv

.

2022

;

6

(

3

):

970

-

975

.

25.

Shi

H

,

He

H

,

Cui

L

, et al.

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

.

Blood

.

2021

;

138

(

14

):

1237

-

1248

.

26.

Patel

AA

,

Ginhoux

F

,

Yona

S

.

Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease

.

Immunology

.

2021

;

163

(

3

):

250

-

261

.

27.

Bigenwald

C

,

Le Berichel

J

,

Wilk

CM

, et al.

BRAF(V600E)-induced senescence drives Langerhans cell histiocytosis pathophysiology

.

Nat Med

.

2021

;

27

(

5

):

851

-

861

.

28.

Xia

C

,

Braunstein

Z

,

Toomey

AC

,

Zhong

J

,

Rao

X

.

S100 proteins as an important regulator of macrophage inflammation

.

Front Immunol

.

2017

;

8

:

1908

.

29.

Sunahori

K

,

Yamamura

M

,

Yamana

J

, et al.

The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis

.

Arthritis Res Ther

.

2006

;

8

(

3

):

R69

.

30.

Rodriguez-Galindo

C

,

Allen

CE

.

Langerhans cell histiocytosis

.

Blood

.

2020

;

135

(

16

):

1319

-

1331

.

31.

Vogler

M

.

BCL2A1: the underdog in the BCL2 family

.

Cell Death Differ

.

2012

;

19

(

1

):

67

-

74

.

32.

Vogler

M

,

Walter

HS

,

Dyer

MJS

.

Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment

.

Br J Haematol

.

2017

;

178

(

3

):

364

-

379

.

33.

Akefeldt

SO

,

Ismail

MB

,

Belot

A

, et al.

Neutralizing anti-IL-17A antibody demonstrates preclinical activity enhanced by vinblastine in Langerhans cell histiocytosis

.

Front Oncol

.

2021

;

11

:

780191

.

34.

Voong

LN

,

Slater

AR

,

Kratovac

S

,

Cressman

DE

.

Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator

.

J Biol Chem

.

2008

;

283

(

14

):

9031

-

9039

.

35.

Yao

Y

,

Xu

Q

,

Kwon

MJ

, et al.

ERK and p38 MAPK signaling pathways negatively regulate CIITA gene expression in dendritic cells and macrophages

.

J Immunol

.

2006

;

177

(

1

):

70

-

76

.

36.

Kadowaki

N

,

Ho

S

,

Antonenko

S

, et al.

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

.

J Exp Med

.

2001

;

194

(

6

):

863

-

869

.

37.

Cros

J

,

Cagnard

N

,

Woollard

K

, et al.

Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors

.

Immunity

.

2010

;

33

(

3

):

375

-

386

.

38.

Lind

NA

,

Rael

VE

,

Pestal

K

,

Liu

B

,

Barton

GM

.

Regulation of the nucleic acid-sensing Toll-like receptors

.

Nat Rev Immunol

.

2022

;

22

(

4

):

224

-

235

.

39.

Shibata

T

,

Sato

R

,

Taoka

M

, et al.

TLR7/8 stress response drives histiocytosis in SLC29A3 disorders

.

J Exp Med

.

2023

;

220

(

9

):

e20230054

.

40.

Fitzgerald

KA

,

Kagan

JC

.

Toll-like receptors and the control of immunity

.

Cell

.

2020

;

180

(

6

):

1044

-

1066

.

41.

Tanji

H

,

Ohto

U

,

Shibata

T

, et al.

Toll-like receptor 8 senses degradation products of single-stranded RNA

.

Nat Struct Mol Biol

.

2015

;

22

(

2

):

109

-

115

.

42.

Zhang

Z

,

Ohto

U

,

Shibata

T

, et al.

Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA

.

Immunity

.

2016

;

45

(

4

):

737

-

748

.

43.

Rafiq

NK

,

Hussain

K

,

Brogan

PA

.

Tocilizumab for the treatment of SLC29A3 mutation positive PHID syndrome

.

Pediatrics

.

2017

;

140

(

5

):

e20163148

.

44.

Bloom

JL

,

Lin

C

,

Imundo

L

, et al.

H syndrome: 5 new cases from the United States with novel features and responses to therapy

.

Pediatr Rheumatol Online J

.

2017

;

15

(

1

):

76

.

45.

Mistry

A

,

Parry

D

,

Matthews

B

,

Laws

P

,

Goodfield

M

,

Savic

S

.

A case of SLC29A3 spectrum disorder-unresponsive to multiple immunomodulatory therapies

.

J Clin Immunol

.

2016

;

36

(

5

):

429

-

433

.

46.

Nofal

H

,

AlAkad

R

,

Nofal

A

, et al.

H syndrome: a review of treatment options and a hypothesis of phenotypic variability

.

Dermatol Ther

.

2021

;

34

(

5

):

e15082

.

47.

Hu-Lieskovan

S

,

Mok

S

,

Homet Moreno

B

, et al.

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

.

Sci Transl Med

.

2015

;

7

(

279

):

279ra41

.

48.

Liu

L

,

Mayes

PA

,

Eastman

S

, et al.

The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4

.

Clin Cancer Res

.

2015

;

21

(

7

):

1639

-

1651

.

49.

Brea

EJ

,

Oh

CY

,

Manchado

E

, et al.

Kinase regulation of human MHC class I molecule expression on cancer cells

.

Cancer Immunol Res

.

2016

;

4

(

11

):

936

-

947

.

50.

Ebert

PJR

,

Cheung

J

,

Yang

Y

, et al.

MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade

.

Immunity

.

2016

;

44

(

3

):

609

-

621

.

51.

Loi

S

,

Dushyanthen

S

,

Beavis

PA

, et al.

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

.

Clin Cancer Res

.

2016

;

22

(

6

):

1499

-

1509

.

52.

Sapkota

B

,

Hill

CE

,

Pollack

BP

.

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells

.

Oncoimmunology

.

2013

;

2

(

1

):

e22890

.

53.

Halbritter

F

,

Farlik

M

,

Schwentner

R

, et al.

Epigenomics and single-cell sequencing define a developmental hierarchy in Langerhans cell histiocytosis

.

Cancer Discov

.

2019

;

9

(

10

):

1406

-

1421

.

54.

Hughes

PE

,

Caenepeel

S

,

Wu

LC

.

Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer

.

Trends Immunol

.

2016

;

37

(

7

):

462

-

476

.

55.

Ugurel

S

,

Rohmel

J

,

Ascierto

PA

, et al.

Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019

.

Eur J Cancer

.

2020

;

130

:

126

-

138

.

56.

Shin

MH

,

Kim

J

,

Lim

SA

,

Kim

J

,

Lee

KM

.

Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade

.

Int J Mol Sci

.

2020

;

21

(

7

):

2531

.

57.

Sengal

A

,

Velazquez

J

,

Hahne

M

, et al.

Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH

.

Blood

.

2021

;

137

(

13

):

1777

-

1791

.

58.

Zoller

EE

,

Lykens

JE

,

Terrell

CE

, et al.

Hemophagocytosis causes a consumptive anemia of inflammation

.

J Exp Med

.

2011

;

208

(

6

):

1203

-

1214

.

59.

Akilesh

HM

,

Buechler

MB

,

Duggan

JM

, et al.

Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes

.

Science

.

2019

;

363

(

6423

):

eaao5213

.

60.

Patel

AA

,

Zhang

Y

,

Fullerton

JN

, et al.

The fate and lifespan of human monocyte subsets in steady state and systemic inflammation

.

J Exp Med

.

2017

;

214

(

7

):

1913

-

1923

.

61.

Landsman

L

,

Bar-On

L

,

Zernecke

A

, et al.

CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival

.

Blood

.

2009

;

113

(

4

):

963

-

972

.

62.

Wei

CW

,

Lee

CY

,

Lee

DJ

, et al.

Equilibrative nucleoside transporter 3 regulates T cell homeostasis by coordinating lysosomal function with nucleoside availability

.

Cell Rep

.

2018

;

23

(

8

):

2330

-

2341

.

63.

Persaud

AK

,

Nair

S

,

Rahman

MF

, et al.

Facilitative lysosomal transport of bile acids alleviates ER stress in mouse hematopoietic precursors

.

Nat Commun

.

2021

;

12

(

1

):

1248

.

64.

Nair

S

,

Strohecker

AM

,

Persaud

AK

, et al.

Adult stem cell deficits drive Slc29a3 disorders in mice

.

Nat Commun

.

2019

;

10

(

1

):

2943

.

65.

Abeykoon

JP

,

Rech

KL

,

Young

JR

, et al.

Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman Disease based on KRAS and MEK alteration status

.

JAMA Oncol

.

2022

;

8

(

12

):

1816

-

1820

.